Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.49 |
| ▸ | CLK2 | P49760 | 5/20 | 0.49 |
| ▸ | CLK3 | P49761 | 5/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760763 | 0.85 | DYRK1A (0.65) | MKNK1DYRK1ACLK2CLK3AKT1 | |
| SCHEMBL758691 | 0.82 | AKT1 (0.52) | MKNK1DYRK1ACLK2CLK3MAPKAPK2 | |
| SCHEMBL10214011 | 0.81 | LRRK2 (0.52) | MKNK1DYRK1ACLK2CLK3MAPKAPK2 | |
| SCHEMBL5508162 | 0.80 | MKNK1 (1.00) | MKNK1JAK2CHEK1DYRK1ACLK2 | |
| SCHEMBL758466 | 0.78 | FLT3 (0.62) | MKNK1JAK2DYRK1ACLK2MAPKAPK2 | |
| SCHEMBL5516155 | 0.78 | MAPKAPK2 (0.57) | MKNK1JAK2DYRK1ACLK2CLK3 | |
| SCHEMBL18487449 | 0.77 | ITK (0.68) | MKNK1JAK2CHEK1DYRK1ACLK2 | |
| SCHEMBL18446365 | 0.75 | DYRK1A (0.59) | MKNK1JAK2CHEK1DYRK1ACLK2 | |
| SCHEMBL18446575 | 0.75 | DYRK1A (0.60) | MKNK1JAK2CHEK1DYRK1ACLK2 | |
| SCHEMBL381383 | 0.75 | IDO1 (0.58) | MAPKAPK2PDPK1LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| CN-1394205-A | Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation | AGOURON PHARMA (US) | 2003-01-29 | — | — | CN | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | MKNK1 1629/4885JAK2 1822/4885CHEK1 1404/4885 |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | MKNK1 107/4885JAK2 359/4885CHEK1 369/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | MKNK1 107/4885JAK2 359/4885CHEK1 369/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | MKNK1 107/4885JAK2 359/4885CHEK1 369/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | MKNK1 241/4885JAK2 443/4885CHEK1 142/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | MKNK1 1629/4885JAK2 1822/4885CHEK1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.